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Herpes simplex virus type 1 encodes two glycopro-
teins, gE and gI, that form a heterodimer on the surface
of virions and infected cells. The gE-gI heterodimer has
been implicated in cell-to-cell spread of virus and is a
receptor for the Fc fragment of IgG. Previous studies
localized the gE-gI-binding site on human IgG to a re-
gion near the interface between the CH2 and CH3 do-
mains of Fc, which also serves as the binding site for
bacterial and mammalian Fc receptors. Although there
are two potential gE-gI-binding sites per Fc homodimer,
only one gE-gI heterodimer binds per IgG in gel filtra-
tion experiments. Here we report production of recom-
binant human Fc molecules that contain zero, one, or
two potential gE-gI-binding sites and use them in ana-
lytical ultracentrifugation experiments to show that
two gE-gI heterodimers can bind to each Fc. Further
characterization of the gE-gI interaction with Fc reveals
a sharp pH dependence of binding, with KD values of
340 and 930 nM for the first and second binding
events, respectively, at the slightly basic pH of the cell
surface (pH 7.4), but undetectable binding at pH 6.0.
This strongly pH-dependent interaction suggests a phys-
iological role for gE-gI dissociation from IgG within
acidic intracellular compartments, consistent with a
mechanism whereby herpes simplex virus promotes in-
tracellular degradation of anti-viral antibodies.
Alphaherpesviruses encode two glycoproteins that bind the
Fc region of IgG to function together as a viral Fc receptor
(FcR).1 This FcR is a heterodimer composed of two type I
transmembrane proteins, glycoprotein E (gE) and glycoprotein
I (gI), on the surface of virions and virally infected cells (1–6).
The herpes simplex virus type 1 (HSV-1) gE protein contains
550 amino acids, including an N-terminal hydrophobic leader
sequence, an 441-residue extracellular region followed by a
predicted single transmembrane helix, and an 106-residue
C-terminal cytoplasmic tail. The HSV-1 gI protein contains 390
amino acids, including an N-terminal hydrophobic leader se-
quence, an 248-amino acid extracellular portion followed by a
predicted single transmembrane helix, and an 94-amino acid
C-terminal cytoplasmic tail. Potential endocytosis signals, in-
cluding YXX motifs (tyrosine followed by any two amino acids
and a hydrophobic residue), dileucine motifs, and acidic cluster
motifs containing phosphorylation sites, are located in the cy-
toplasmic tails of gE and gI. Transfection experiments in HeLa
cells to express HSV-1 gE proteins with truncated cytoplasmic
tails localized two sorting signals: one located within an acidic
stretch and a second located within a stretch of residues con-
taining two tyrosine-based tetrapeptide motifs (7). These find-
ings are consistent with studies of the gE cytoplasmic domains
of two commonly studied alphaherpesviruses, pseudorabies vi-
rus (PRV) and varicella zoster virus (VZV), that identified
functional roles for acidic motifs containing consensus casein
kinase II phosphorylation sites and tyrosine motifs (8–12). A
methionine-leucine endocytosis signal in the cytoplasmic tail of
VZV gI has been shown to be important for the efficient inter-
nalization of gI in transfected HeLa cells (13).
In vitro and in vivo studies characterizing the FcR function of
the gE-gI heterodimer have underscored its importance for
alphaherpesviruses in escaping antibody-dependent compo-
nents of the immune response. Mutational studies determined
that the HSV-1 gE-gI heterodimer is required for high affinity
binding of monomeric IgG, whereas gE alone is a monomeric,
lower affinity FcR that only binds IgG-antigen immune com-
plexes, such as IgG-coated erythrocytes (3, 14). FcR activity has
also been demonstrated for gE-gI complexes from VZV and
PRV (15, 16). The gE-gI complex may play a protective role
whereby binding of the Fc portion of IgG could sterically inhibit
neutralization of the virus or infected cells by anti-HSV anti-
bodies as well as complement- and cell-mediated lysis of in-
fected cells (17, 18). Additional data suggest that gE-gI binds
anti-HSV IgG by a process known as antibody bipolar bridging
in which the Fab domains of an anti-HSV antibody bind to
specific viral antigens, and the Fc domain binds to gE-gI. FcR-
mediated antibody bipolar bridging that interferes with anti-
body- and complement-mediated neutralization has been dem-
onstrated on the surfaces of HSV-1 virions and virally infected
cells (19). Furthermore, under conditions in which antibody
bipolar bridging could occur, gE was required for the protection
of infected cells from antibody-dependent cell-mediated cyto-
toxicity, C1q complement binding, and granulocyte attachment
(20, 21). More recently, a functional HSV-1 FcR was shown to
be critical for protecting HSV-1-infected mice from attack by
human anti-HSV IgG (22).
Several properties of IgG binding by gE-gI have been eluci-
dated. Early studies showed that IgG binding by HSV-1-in-
fected cells is both species- and subtype-specific. Thus, rabbit
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IgG and human IgG (hIgG) subtypes 1, 2, and 4 (hIgG1, hIgG2,
and hIgG4) bind to HSV-1, but rodent IgG and many allotypes
of hIgG3 do not bind (23–27). Correlating with these results,
the affinities of recombinant, soluble gE-gI for different hIgG
subtypes derived from a surface plasmon resonance-based
binding assay resulted in a rank ordering of the hIgG binding
preference as follows: hIgG4  hIgG1  hIgG2 (equilibrium
dissociation constant (KD) values ranging from 200 to 400 nM
 hIgG3 (undetectable binding) (28). When the arginine at
position 435 of hIgG3 was substituted with a histidine, which is
the amino acid found at position 435 in hIgG1, hIgG2, and
hIgG4, binding of gE-gI was partially restored (KD 1 M), and
conversely, when histidine 435 of hIgG4 was replaced with an
arginine, binding was undetectable (28). These results suggest
that the gE-gI-binding site on Fc includes residue 435 at the
CH2-CH3 domain interface of Fc, consistent with the finding
that fragment D of protein A, which also binds to the CH2-CH3
domain interface of Fc, inhibits binding of Fc fragments to
HSV-1-infected cells (29).
In addition to gE-gI, other proteins known to recognize the
CH2-CH3 domain interface of Fc regions of antibodies include
bacterial FcRs (protein A and protein G), mammalian FcRs
(FcRI, a receptor for IgA, and FcRn, which transports IgG
from the mother to the fetus or neonate), and rheumatoid
factor, an autoimmune antibody that recognizes the Fc portion
of IgG and IgM. Each of these Fc-binding proteins interacts
with Fc at the CH2-CH3 domain junction of each subunit of the
Fc dimer with a binding stoichiometry of two Fc-binding pro-
teins per Fc molecule (30–36). Other FcRs, such as FcRI,
FcRII, FcRIII, and FcRI, mediate the interaction with their
respective Fc partners via a portion of the CH1-CH2 hinge and
a region of the CH2 domain in an asymmetric interaction in
which only one FcR binds to each Fc dimer (37–39). Although
gE-gI shares an Fc-binding site with protein A, protein G,
FcRn, and rheumatoid factor, our earlier characterization of
the interaction between a soluble version of gE-gI and IgG
suggested that only one gE-gI binds per IgG molecule (28).
Because FcRn can form 1:1 complexes with IgG even though
two FcRn molecules bind per IgG at equilibrium (40–42), we
conducted additional experiments to investigate the binding
stoichiometry of the gE-gI/Fc interaction. By using recombi-
nant human Fc molecules that contain zero, one, or two poten-
tial gE-gI-binding sites, we determined the binding stoichiom-
etry of gE-gI and Fc in an analytical ultracentrifugation assay.
These experiments demonstrate that one or two gE-gI mole-
cules can bind per Fc homodimer, analogous to other 2:1 FcR/Fc
interactions in which the Fc-binding protein recognizes each of
the CH2-CH3 domain interfaces on homodimeric Fc.
We also examined the binding of gE-gI to Fc as a function of
pH, discovering that gE-gI binds tightly to Fc at neutral or
slightly basic pH but undetectably at acidic pH. This pH-de-
pendent Fc binding profile is opposite to that of FcRn, which
exhibits a sharply pH-dependent binding profile with binding
at acidic pH  6.5 but not at neutral pH (43–45). None of the
other FcR/Fc interactions, however, are known to be affected
by pH changes near neutral. The sharp pH dependence of the
FcRn/Fc interaction is critical to its function by allowing FcRn
to bind IgG in the acidic environment of intracellular transport
vesicles and release IgG at the slightly basic pH of the blood-
stream. We suggest that the opposite, but equally striking,
pH-dependent binding properties of the gE-gI/Fc interaction
play a role in gE-gI function, in the transport of anti-HSV
antibodies from the cell surface to lysosomes for degradation.
EXPERIMENTAL PROCEDURES
Construction of and Expression of Soluble gE-gI and gE Vectors—A
soluble version of the gE-gI heterodimer was expressed in CHO cells as
described previously (28). Soluble gE-gI was also expressed in insect
cells infected with a recombinant baculovirus encoding both gE and gI.
For insect cell expression, standard PCR subcloning techniques were
used to insert fragments of the gE (encoding residues 1–419) and gI
(encoding residues 1–266) genes of HSV strain KOS into the BglII-
EcoRI sites (gE) and BamHI site (gI) of the pAcUW51 dicistronic bacu-
lovirus expression vector (Pharmingen). An oligo-linker encoding a
factor Xa cleavage site followed by six histidine residues and a stop
codon was ligated into the vector in-frame with the 3 end of the gI gene.
An expression vector for gE alone with a C-terminal six-histidine tag
was constructed by PCR subcloning a fragment of the gE gene of HSV
strain KOS (encoding residues 1–390) into the BglII-EcoRI sites of
pAcUW51 (Pharmingen) in-frame with an oligo-linker encoding a factor
Xa cleavage site followed by six histidine residues and a stop codon at
the 3 end of the gE gene. The open reading frames of all constructs
were completely sequenced. Recombinant baculovirus stocks for expres-
sion of gE-gI and gE were generated by cationic liposome cotransfection
of the dicistronic expression plasmid with linear wild-type baculovirus
DNA in High 5 insect cells (Invitrogen) as described by the manufac-
turer. The gI construct used in these experiments and in previous
studies (28, 46) contains a deletion of residues 221–227, which comprise
the last copy of a seven-amino acid repeat (XXXPSTT, where X is any
amino acid) in the putative stalk region near the C terminus. The
alteration in this region does not affect the Fc-binding function of the
gE-gI heterodimer but significantly increases the expression levels of
the heterodimer in insect cells, with the yield increasing from 200 g
of purified gE-gI heterodimer per liter for expression of the unaltered
construct to 10 mg/liter for the altered construct (data not shown).
Purification of Soluble gE-gI Heterodimer—Soluble gE-gI was ini-
tially purified from either CHO cell supernatants directly or pH-ad-
justed insect cell supernatants by binding to an IgG affinity column
(constructed by covalently coupling human IgG to Sepharose) at pH 7.4
and eluting at pH 11.5 as described (28). After the pH-dependent
binding of gE-gI to Fc was discovered, we used a gentler protocol
involving a pH 5.5 buffer (50 mM sodium citrate, 150 mM NaCl, 1 mM
EDTA) to elute gE-gI from the IgG affinity column. Proteins eluted from
the IgG affinity column were subsequently purified by size-exclusion
chromatography on a Superdex 200 HR 10/30 or Superdex 200 HiLoad
16/60 column (Amersham Biosciences).
Purification of Soluble gE—Insect cell supernatants containing se-
creted gE were buffer exchanged into nickel-binding buffer (40 mM Tris,
pH 8, 300 mM NaCl, 10 mM imidazole) and passed over a Ni-NTA-
agarose column (Qiagen). Bound protein was eluted in buffer containing
40 mM Tris, pH 8, 300 mM NaCl, 250 mM imidazole and further purified
by size-exclusion chromatography on a Superdex 75 HiLoad 26/60 col-
umn (Amersham Biosciences) that was equilibrated in 20 mM Tris, pH
7.8, 150 mM NaCl, 1 mM EDTA. Analysis of the peak fractions on a 12%
SDS-PAGE gel showed a band migrating with an apparent molecular
mass of 47 kDa (data not shown). Approximately 70 mg of gE were
obtained per liter of insect cell supernatants.
Expression of Wild-type and Mutant Human Fc Proteins—Three
forms of human Fc, wild-type Fc (wtFc), heterodimeric Fc (hdFc), and
non-binding Fc (nbFc), which contain two, one, and zero potential
gE-gI-binding sites, respectively, were constructed using a human IgG1
heavy chain cDNA (provided by David Cosman, Immunex, Seattle) as
described previously for expression of the analogous forms of rat Fc (34).
For expression of wild-type Fc, the DNA encoding the Fc region of
human IgG1 (residues 223–447) was PCR-amplified and subcloned
in-frame with the rat IgG2a signal sequence into pBJ5-GS, a mamma-
lian expression vector that carries the glutamine synthetase gene as a
means of selection and amplification in the presence of the drug methi-
onine sulfoximine (MSX) (47). The expression vector encoding wtFc was
transfected into CHO cells using the LipofectAMINE 2000 protocol
(Invitrogen) with selection and amplification of stable cell lines using
methionine sulfoximine as described (28, 43). Clones were screened for
secretion of Fc by testing the supernatants for binding to protein A-
Sepharose, as visualized on a Coomassie-stained 12% SDS-PAGE gel
run under reducing and non-reducing conditions. Positive clones
yielded a protein migrating with apparent molecular masses of 35 and
70 kDa under reducing and non-reducing conditions, respectively.
The nbFc expression construct was generated by mutating residues
located in the vicinity of the CH2-CH3 domain interface of wtFc, a region
of Fc that has been implicated in gE-gI binding (28). The QuikChange
protocol (Stratagene) was used to make the following substitutions,
which are analogous to substitutions introduced into rat Fc to abrogate
binding to rat FcRn (34): Met-252 to Gly, Ile-253 to Gly, His-310 to Glu,
His-433 to Glu, His-435 to Glu, and Tyr-436 to Ala. PCR was used to
add a factor Xa cleavage site and six histidines to the 3 end of the nbFc
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construct. This DNA encoding nbFc was subcloned into pBJ5-GS as
described above for wtFc. The expression vectors encoding wtFc and
nbFc were cotransfected into CHO cells using the LipofectAMINE 2000
protocol (Invitrogen) with selection and amplification of stable cell lines
using MSX as described (28, 43). Supernatants from clones that were
viable in MSX were assayed for expression of either hdFc or nbFc by
binding to Ni-NTA-agarose (Qiagen) and for expression of wtFc or hdFc
by binding to FcRn-Sepharose, similar to the identification of clones
expressing rat wtFc, hdFc, and nbFc (34). Positive clones secreted a
mixture of hdFc, which is a heterodimer containing one wtFc and one
nbFc chain, and wtFc and nbFc homodimers. On a 10% SDS-PAGE gel
run under reducing conditions, nbFc migrates as a band of apparent
molecular mass 37 kDa, wtFc migrates at an apparent molecular mass
of 35 kDa, and hdFc migrates as two bands, 37 and 35 kDa (data not
shown).
Purification of Human Fc Proteins—CHO cells were grown to con-
fluence in 15-cm tissue culture plates, and supernatants were collected
every 2–3 days. wtFc was purified from the harvest media using a
modification of a previously described functional purification for rat Fc
involving pH-dependent binding to a rat FcRn-Sepharose column (34).
The pH of supernatants containing wtFc was adjusted to 5.8 with the
addition of 1 M citrate buffer, pH 5.5 (85 ml of citrate buffer/600 ml of
supernatant), and then passed over the FcRn-Sepharose column. The
column was washed with 50 mM citrate buffer, pH 5.5, 150 mM NaCl, 1
mM EDTA, 0.1% (w/v) NaN3 and then eluted with 50 mM Tris, pH 8.3,
150 mM NaCl, 1 mM EDTA. Eluted proteins were concentrated in a
15-ml Amicon (10,000-Da cut-off) spin concentrator and either stored or
loaded onto a Superdex 75 HR 10/30 or Superdex 75 HiLoad 16/60
column (Amersham Biosciences) that was equilibrated in 20 mM Hepes,
pH 7.8, 150 mM NaCl. Peak fractions were concentrated to 15 mg/ml
and stored at 4 °C.
hdFc and nbFc were purified from media harvested from CHO cells
that secrete a mixture of wtFc, hdFc, and nbFc. The purification scheme
is similar to that used to purify rat hdFc and nbFc (34). In the first step,
hdFc and nbFc are separated from wtFc using a Ni-NTA-agarose col-
umn (Qiagen) to which the double histidine tag of nbFc and the single
histidine tag of hdFc bind. In the second step, hdFc and nbFc are
separated at low pH by passage over an FcRn-Sepharose column, to
which hdFc binds and nbFc flows through. Supernatants containing
wtFc, hdFc, and nbFc were buffer exchanged into 40 mM Tris, pH 8, 300
mM NaCl, 10 mM imidazole, and 5% (w/v) glycerol and then mixed in
batch with Ni-NTA-agarose. The Ni-NTA-agarose was washed with 40
mM Tris, pH 8, 300 mM NaCl, 10 mM imidazole and eluted with 40 mM
Tris, pH 8, 300 mM NaCl, 250 mM imidazole. Peak fractions were
collected, concentrated, and buffer exchanged in 50 mM citrate buffer,
pH 5.5, 150 mM NaCl, 1 mM EDTA, and loaded onto a rat FcRn-
Sepharose column. nbFc flows through this column, and hdFc was
eluted at pH 8.3. To control for oversaturation of the FcRn column, the
flow-through was passed over the column repeatedly until the final two
passes showed no evidence of hdFc elution at pH 8.3. hdFc and nbFc
were concentrated and buffer exchanged in 20 mM Hepes, pH 7.8, 150
mM NaCl, and then either stored or loaded onto a size-exclusion column
as described for wtFc.
Protein concentrations were determined spectrophotometrically us-
ing extinction coefficients at 280 nm of 69,280 (wtFc, hdFc, and nbFc),
87,630 (gE-gI), and 64,010 M1 cm1 (gE), which were calculated from
the amino acid sequence using the ProtParam tool in Expasy (48).
Analytical Ultracentrifugation—wtFc, hdFc, or nbFc were each
mixed with insect cell-expressed gE-gI, which contains a C-terminal
His6 tag on gI, in various molar ratios from 1:1 (4.9 M gE-gI, 4.9 M Fc)
to 6:1 (29.4 M gE-gI, 4.9 M Fc) in 20 mM Hepes, pH 7.8, 150 mM NaCl.
Fc samples were examined alone at a concentration of 4.9 M; gE-gI was
examined alone at concentrations of 9.8 and 14.7 M, and gE was
examined alone at a concentration of 12 M.
Sedimentation velocity experiments were carried out with two-sector
charcoal-filled Epon 12-mm centerpieces equipped with quartz windows
that were loaded with 416 l of protein and 423 l buffer as a reference.
The samples were spun at 42,000 rpm at 20 °C in an An-60 Ti rotor in
a Beckman Ultima XL-I analytical ultracentrifuge. Radial scans using
absorbance optics were collected at 230, 250, or 280 nm with a step size
of 0.003 cm in continuous mode at an interval of about 4 min until the
samples reached the bottom of the cell. Data were analyzed using the
c(s) routine in the program SEDFIT (49), which uses maximum entropy
regularization and a finite element solution to the Lamm equation to fit
the sedimentation data. The c(s) analysis results in a differential sed-
imentation coefficient distribution in which sample diffusion has been
accounted for explicitly. The apparent sedimentation coefficients (s*)
reported in these studies were not corrected to standard conditions due
to the complications of calculating partial specific volumes for the Fcs
and gE-gI since they are glycosylated; however, all s* values were
determined under identical conditions. In the samples in which there
was one predominant species, molecular masses were estimated using
the fit value for the frictional ratio. The absorbance of samples used for
centrifugation was measured at 230, 250, and 280 nm, and a scale factor
between wavelengths was calculated for each set of samples with a
given molar ratio. c(s*) distributions were scaled such that all have
units of A280 per Svedberg.
Biosensor Studies—Surface plasmon resonance studies were per-
formed using a BIAcore 2000 instrument. Purified recombinant wtFc
fragment in 10 mM sodium acetate, pH 4.6, was immobilized on a
research-grade CM5 biosensor chip using primary amine coupling as
described in the Biacore manual. For gE-gI binding to immobilized Fc,
one flow cell was mock coupled with buffer only, whereas the other
three flow cells were coupled with Fc at low coupling densities (75–467
resonance units (RU)) limiting the possibility of mass transport (50).
Mass transport was not observed in a test in which gE-gI was injected
at various flow rates, and the sensorgrams were superimposed to check
whether or not the association phases aligned (data not shown). 3-Fold
dilutions of a concentrated stock of purified CHO cell-expressed, soluble
gE-gI were made starting at 10.9 M and ending at 0.5 nM. For each
binding experiment at a different pH, the pH of a triple buffer contain-
ing 25 mM sodium acetate, 25 mM MES, 25 mM bis-Tris propane, 150 mM
NaCl, 3 mM EDTA, and 0.005% (v/v) P-20 surfactant was adjusted
appropriately. 250 l of each of the eight gE-gI concentrations and at
least one buffer sample were injected at 50 l/min, and RUs were
recorded as a function of time. After the each injection of gE-gI, a 30-s
injection of 250 mM di-ammonium hydrogen citrate, pH 5.0, was used to
disrupt the binding and regenerate the surface.
Sensorgrams for the binding of gE-gI to immobilized wtFc at pH
values between 6.0 and 8.2 in steps of 0.2 pH units were processed using
the Scrubber software package (BioLogic Software, Campbell, Austra-
lia; www.biologic.com.au) and analyzed using single-site and bivalent
ligand models in Clamp99 (51), a global fitting program that simulta-
neously fits the association and dissociation phases for all curves in a
concentration set. The bivalent ligand model describes two sequential
binding events for gE-gI binding to homodimeric Fc, yielding two sets of
apparent on- and off-rate constants. Equilibrium dissociation constants
(KD) were calculated from the ratio of the apparent dissociation and
association rate constants, yielding apparent KD values for the first and
second binding events (KD1(app) and KD2(app)). The first apparent on-rate
constant was converted to an intrinsic rate constant using a statistical
factor to account for the two potential binding sites on Fc to which the
first gE-gI molecule can bind, and the second apparent off-rate was
converted to an intrinsic off-rate to account for the two sites on the fully
bound complex from which the first dissociation event can occur. Thus,
the intrinsic on-rate constant for the first gE-gI molecule is half that of
the apparent rate constant (k1on  k1on(app)/2), and the intrinsic off-rate
constant for the second molecule is half that of the apparent rate
constant (k2off  k2off(app)/2). For independent binding sites, the calcu-
lated stepwise dissociation constants (KD1(app) and KD2(app)) are related
to the intrinsic binding constants for the first and second binding events




Bulk refractive index and mass transport parameters were not fit, and
curves with 2 RU or less binding were omitted from the fits. The quality
of the fits for data generated at pH 6.2, 6.4, and 6.6 was improved by
fixing the concentration parameter for Fc on the chip at the average
value for the other pH values. Intrinsic equilibrium constants were
plotted as equilibrium association constants (KA), where KA  1/KD,
versus pH. Linear regression analysis was used to determine the slope
of the best line through the data points between pH 6.4 and 7.0.
For gE binding to immobilized Fc, one flow cell was mock-coupled
with buffer only, whereas the other three flow cells were coupled with
wtFc, hdFc, or nbFc at densities between 200 and 600 RU. 2-Fold
dilutions of a concentrated stock of purified, soluble gE were made
starting at 105 M and ending at 200 nM. 200 l of each of the gE
concentrations and at least two buffer samples were injected at 5
l/min, and the RU was recorded as a function of time. Binding of gE to
immobilized Fc was examined at pH 8.0 (50 mM Hepes, pH 8, 150 mM
NaCl, 3 mM EDTA, and 0.005% (v/v) P-20 surfactant) and pH 6.0 (50 mM
sodium phosphate buffer, pH 6, 150 mM NaCl, 3 mM EDTA, and 0.005%
(v/v) P-20 surfactant), and sensorgrams were processed and analyzed
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using the Scrubber software package (BioLogic Software Pty. Ltd.,
www.biologic.com.au). The KD values were determined by plotting the
response in the plateau region versus the logarithm of the analyte
concentration for each concentration series and fitting the data to a
single-site binding model.
RESULTS
Expression and Purification of gE-gI and Human Fc Pro-
teins—Soluble gE-gI was produced and purified from the su-
pernatants of transfected CHO cells or baculovirus-infected
insect cells expressing the gE and gI ectodomains as described
under the “Experimental Procedures” and Ref. 28. The result-
ing protein is a 1:1 gE-gI heterodimer composed of residues
21–399 of gE and residues 21–246 of gI (not including the
hydrophobic leader sequences and transmembrane and cyto-
plasmic domains of both proteins) (28).
To investigate the interactions between gE-gI and IgG, we
expressed mutant and wild-type forms of the Fc fragment of
human IgG. Previous studies (28) with recombinant soluble
gE-gI that compared the binding affinities for the human IgG
subtypes showed that residue 435 at the CH2-CH3 domain
interface within the Fc region of IgG is critical for gE-gI binding
to IgG. We sought to define further the gE-gI interaction inter-
face with IgG by constructing mutant Fc molecules in which
residues in the putative gE-gI-binding site were mutated on
one or both of the Fc subunits, analogous to previous studies of
mutant rat Fc proteins used to investigate the rat FcRn/Fc
interaction (34).
A wild-type Fc (wtFc) expression vector was constructed to
express the Fc region of human IgG1. A nbFc construct was
generated from the wtFc construct by mutating six residues
located in the CH2-CH3 domain (Met-252 to Gly, Ile-253 to Gly,
His-310 to Glu, His-433 to Glu, His-435 to Glu, and Tyr-436 to
Ala) interface and adding a C-terminal His6 tag. Four of the six
residues that were substituted are part of a consensus binding
site on Fc for protein A, protein G, rheumatoid factor, rat FcRn,
and the Fc-III peptide (33, 52). Cotransfection of the wtFc and
nbFc expression plasmids into CHO cells resulted in secretion
of a mixture of wtFc homodimers, nbFc homodimers, and a
hdFc that is composed of one wtFc chain and one nbFc chain.
These three forms of human Fc were isolated from transfected
cells as described previously for the wild-type, non-binding, and
heterodimeric forms of rat Fc (34). Briefly, wtFc was purified
from the supernatants of CHO cells that were transfected with
only wtFc by taking advantage of its pH-dependent binding to
FcRn. Thus, supernatants were passed over an FcRn-Sepha-
rose column at pH 5.5 and eluted at pH 8.3. To obtain nbFc and
hdFc, transfected CHO supernatants were passed over a Ni-
NTA column, which binds the His-tagged Fcs (nbFc and hdFc).
The eluant was then loaded onto the FcRn-Sepharose column
at pH 5.5, which binds hdFc but not nbFc.
wtFc and hdFc, but Not nbFc, Bind to gE-gI—We used an
analytical ultracentrifugation sedimentation velocity assay to
compare the binding of purified gE-gI heterodimers to wtFc,
hdFc, and nbFc. Data analyses were performed with the pro-
gram SEDFIT using the c(s) distribution of sedimentation co-
efficients, which allows for visualization of differentially sedi-
menting species as peaks in the distribution function (49). For
each of the Fc molecules, the distribution of sedimentation
coefficients was monitored in the presence and absence of gE-
gI, with a change in the distribution indicating the formation of
a new species. When equimolar concentrations of wtFc, hdFc,
and nbFc were spun individually and their distribution func-
tions were analyzed, each of the samples migrated with an
apparent sedimentation coefficient (s*) of 3.7 S with nearly
overlapping distribution functions when the three samples
were compared (Fig. 1A). These analyses show that the wtFc,
hdFc, and nbFc proteins are dimers with the expected molec-
ular masses that have similar hydrodynamic properties. The
gE-gI alone sample had an s* of 3.7 S and a small peak at 5.2
S that may be a small amount of aggregated gE-gI or an
unidentified contaminant (Fig. 1A). Because the s* values and
peak profiles for the Fc proteins and gE-gI are virtually indis-
tinguishable, only one peak that corresponds to both proteins
would be observed in a mixture of gE and a non-binding version
of Fc. Thus, when nbFc was mixed with gE-gI in various molar
ratios, the s* value of the major species remained constant at
3.7 S, and the distribution pattern did not change significantly
(Fig. 1B). When hdFc was mixed with gE-gI in various molar
ratios, the distribution function changed with the addition of
gE-gI as indicated by the appearance of a new peak at 5.45 S
(Fig. 1C). Likewise, sedimentation of the wtFc samples with
gE-gI resulted in additional species with s* values ranging
from 5.6 to 6.55 S, depending on the wtFc:gE-gI molar ratio
(Fig. 1D).
The change in the distribution of apparent sedimentation
coefficients when hdFc and wtFc were mixed with gE-gI indi-
cates that hdFc and wtFc bind gE-gI, whereas the lack of
change in the distribution function when nbFc was mixed with
gE-gI indicates that nbFc does not bind detectably to gE-gI.
Thus, at least some of the residues in the CH2-CH3 domain
interface that were mutated to make nbFc from wtFc contrib-
ute significantly to the binding surface with gE-gI. In addition,
the ability of hdFc to bind gE-gI indicates that the gE-gI-
binding site on Fc is contained primarily within a single wild-
type Fc subunit rather than being composed of residues from
both of the Fc subunits.
Two gE-gI Heterodimers Bind to Each wtFc—Sedimentation
velocity centrifugation experiments were also performed to
compare the stoichiometry of gE-gI binding to Fc molecules
with two, one, or zero potential gE-gI-binding sites. Samples
contained gE-gI and either wtFc, hdFc, or nbFc in molar ratios
of 1:1, 2:1, 4:1, and 6:1 (gE-gI:Fc). The data were analyzed as
described above. If the stoichiometry of gE-gI binding to Fc is
1:1, identical c(s*) distributions would be observed for wtFc and
hdFc, independent of the concentration of gE-gI. If the stoichi-
ometry of gE-gI binding to Fc is 2:1, new species with larger s*
values will appear as the molar ratio of gE-gI:wtFc is increased,
eventually forming a saturated 2:1 gE-gIwtFc complex,
whereas the same species will be present for hdFc with all of
the molar ratios. For the 1:1 sample containing hdFc and gE-gI,
the majority of the sample sediments at 5.45 S. As the amount
of gE-gI is increased and the concentration of hdFc remains
fixed, the height and position of the peak at 5.45 S are constant,
whereas the height of the peak at 3.7 S, which corresponds to
excess gE-gI, increases (Fig. 1C). With wtFc and gE-gI, the
species observed in the 1:1 sample migrates at 5.6 S, which is
slightly larger than in the 1:1 hdFc sample, likely representing
a mixture of primarily 1:1 complexes with some 2:1 complexes
(Fig. 1E). As the amount of gE-gI is increased, the original peak
at 5.6 S shifts to 6, 6.45, and 6.55 S in the 2:1, 4:1, and 6:1
samples, respectively, indicating that a new species is formed
that saturates near the 4:1 input molar ratio (Fig. 1D). The
increase in height of the 3.7 S peak as the molar ratio is
increased from 2:1 to 4:1 and 6:1 indicates excess gE-gI, con-
sistent with a 2:1 gE-gI/Fc stoichiometry. A comparison of the
distribution of apparent sedimentation coefficients between
samples containing nbFc, hdFc, and wtFc at each molar ratio
tested is shown in Fig. 1, E–H. These data are consistent with
a model whereby wtFc binds two molecules of gE-gI, one per Fc
polypeptide chain, and hdFc binds only one molecule of gE-gI
because it contains only a single potential gE-gI-binding site.
Biosensor Binding Experiments Support a Bivalent Binding
Model—The binding properties for the interaction between
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gE-gI and wtFc were further characterized by using a surface
plasmon resonance assay. Recombinant wtFc (the “ligand”) was
immobilized at low coupling densities on the surface of a bio-
sensor chip, and the binding of soluble gE-gI (the “analyte”)
was assayed at pH 7.4. Global fitting algorithms were used to
fit the kinetic data to a single-site binding model from which a
single equilibrium dissociation constant (KD) is derived and to
a bivalent ligand model that assumes that the wtFc ligand
contains two independent binding sites for gE-gI, each of which
can be described by a KD value (KD1 and KD2) (Fig. 2, A and B).
The derived KD value for gE-gI binding to wtFc assuming a
single-site binding model was 340 nM, similar to previous sur-
face plasmon resonance-based binding studies analyzing hu-
man IgG1 binding to immobilized gE-gI, in which the derived
KD value for a 1:1 binding model was280 nM (28). The present
biosensor data for the interaction between soluble gE-gI and
immobilized wtFc were better described by the bivalent ligand
model than the single site model (Fig. 2, A and B), consistent
with the analytical centrifugation studies demonstrating that
gE-gI can bind to wtFc with a 2:1 binding stoichiometry (Fig.
1D). By using the bivalent ligand model, we determined KD
values of 343 nM (KD1) and 928 nM (KD2) for binding of gE-gI to
FIG. 1. Binding of gE-gI to nbFc, hdFc, and wtFc as determined by sedimentation velocity. Various concentrations of gE-gI were mixed
with a fixed concentration of nbFc, hdFc, or wtFc at pH 7.8 and spun in an analytical ultracentrifuge. The distribution of apparent sedimentation
coefficients (c(s*)) in units of A280/Svedberg is shown for each protein mixture. A, nbFc, hdFc, and wtFc alone and gE-gI alone (the three Fc species
have nearly identical c(s*) distributions). B, 1:1, 2:1, 4:1, and 6:1 molar ratios of gE-gI with nbFc. C, 1:1, 2:1, 4:1, and 6:1 molar ratios of gE-gI with
hdFc. D, 1:1, 2:1, 4:1, and 6:1 molar ratios of gE-gI with wtFc. E, 1:1 molar ratios of gE-gI with nbFc, hdFc, and wtFc. F, 2:1 molar ratios of gE-gI
with nbFc, hdFc, and wtFc. G, 4:1 molar ratios of gE-gI with nbFc, hdFc, and wtFc. H, 6:1 molar ratios of gE-gI with nbFc, hdFc, and wtFc.
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the first and the second binding sites on wtFc, respectively
(Table I). Because the affinities of the two gE-gI-binding sites
are similar, binding of one molecule of gE-gI does not signifi-
cantly affect the binding of the second molecule. By using a
single-site binding model for the interaction between immobi-
lized hdFc and injected gE-gI, we derive a KD of 447 nM (data
not shown). Thus, the single gE-gI-binding site on hdFc has
similar binding properties to each of the two gE-gI-binding
sites on wtFc.
gE-gI and gE Bind Fc in a pH-dependent Manner—To inves-
tigate the possibility that gE-gI binding to Fc is pH-dependent,
we conducted a series of surface plasmon resonance-based
binding experiments at different pH values. Recombinant wtFc
was immobilized on the surface of a biosensor chip; the binding
of soluble gE-gI was assayed at different concentrations be-
tween pH values of 6.0 and 8.2 in 0.2 pH unit increments; and
the binding data were fit to a bivalent ligand model (Table I).
From pH 7.4 to 8.2, the KD values (KD1  240–343 nM; KD2 
669–928 nM) are relatively constant. At lower pH values, how-
ever, the affinities of the gE-gI interaction with wtFc decrease,
dropping by 10-fold at pH 6.6 and becoming undetectable at pH
6.0 at concentrations up to 11 M (Fig. 2C). The reduction in
binding as the pH becomes more acidic is primarily the effect of
an increased off-rate (Table I).
To estimate the number of ionizable residues involved in the
pH-dependent affinity change observed for the gE-gI/Fc inter-
action, we plotted the equilibrium association constants (KA1
and KA2) as a function of pH. The slope of the steepest section
of this plot gives the net number of protons that are either
released or taken up when gE-gI binds to wtFc over a given pH
range. The slopes of the transitions between pH 6.4 and 7.0 are
2.1 and 2.2 for the first and second binding sites on wtFc,
respectively, suggesting that two protons are released at each
binding site on wtFc when gE-gI binds (Fig. 3). The steep
transition in binding affinities suggests that the gE-gI/Fc bind-
ing interface involves two ionizable residues with pKa values
between pH 6.4 and 7.0. Histidines, which have a pKa between
6 and 7 (53), are likely candidates for mediating pH-dependent
FIG. 2. Biosensor analyses of gE-gI and gE binding to Fc. Recombinant wtFc derived from human IgG1 was immobilized on the surface of
a biosensor chip using primary amine coupling. A and B, comparison of fits (thin black lines) and associated residuals for sensorgrams (thick colored
lines) collected from the indicated concentrations of gE-gI injected at pH 7.4 over a flow cell coupled with wtFc to 75 RU. C, sensorgrams collected
from the indicated concentrations of gE-gI injected at pH 6.0 over a flow cell coupled with wtFc to 75RU. D, plot of equilibrium-binding response
(Req) versus concentration of gE derived from biosensor experiments in which gE was injected at pH 8.0 and pH 6.0 over a flow cell coupled with
wtFc. Best fit binding curves to the experimental data points are shown as continuous lines. Due to experimental limitations, data points at
saturating concentrations of gE were unable to be obtained. Data collected at pH 8.0 are indicated in blue circles, and data collected at pH 6.0 are
indicated in pink squares.
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interactions near neutral pH. At basic pH, where gE-gI binds
the Fc of IgG, histidines are uncharged, whereas at acidic pH,
histidines are protonated and positively charged. One mecha-
nism to explain the pH-dependent interaction between gE-gI
and Fc is that the interface between gE-gI and Fc contains two
histidines that disrupt hydrophobic contacts or contacts with a
positively charged residue when protonated at acidic pH. Al-
though our analysis does not allow insight into which binding
partner contains the two ionizable residues, it is tempting to
speculate that Fc His-435 and perhaps one of the other con-
served histidines at the CH2-CH3 interface (His-310 or His-433)
are involved in the pH-dependent interaction with gE-gI. Al-
ternatively, conserved histidines in gE and/or gI may also be
involved.
To further characterize the pH dependence of the gE-gI in-
teraction with Fc, we tested whether isolated gE monomers
bind to Fc with pH dependence using the surface plasmon
resonance assay. Because the on- and off-rates for the gE/Fc
interaction are too fast to obtain useful kinetic data (data not
shown), the binding affinity was determined using an equilib-
rium-binding method. Although Fc contains two potential bind-
ing sites for gE, a single-site model was used to fit the data
because the binding was too weak to allow accurate fitting of a
two-site model. At pH 8, the derived KD was 30 M, which is
100-fold weaker than the gE-gI/Fc interaction (Fig. 2D), con-
sistent with previous characterizations of gE alone as a low
affinity FcR that binds IgG-antigen immune complexes but not
isolated IgG (3, 14). Similar to the gE-gI/Fc interaction, the
gE/Fc interaction is pH-dependent with binding becoming too
weak to calculate a KD at pH 6 (Fig. 2D). Thus, the pH depend-
ence of the gE-gI interaction with IgG is likely to involve
residues on gE and/or Fc.
DISCUSSION
The herpesvirus gE-gI heterodimer is found on the surface of
virions and infected cells and binds the Fc region of IgG (1–6).
Previous surface plasmon resonance assays of the interaction
between soluble gE-gI and hIgG revealed that gE-gI binds to
the hIgG1, hIgG2, and hIgG4 subclasses with affinities 300
nM but does not show detectable binding to hIgG3 at concen-
trations up to 3 M (28), consistent with IgG binding studies
using HSV-1-infected cells (24, 26, 27). The previous biosensor
study also identified residue 435, located in the Fc region of the
IgG heavy chain, as a critical residue for IgG binding by gE-gI
(28), consistent with the observation that a proteolytic frag-
ment of protein A, which binds to the CH2-CH3 domain inter-
face of Fc containing His-435, inhibited the binding of Fc frag-
ments to HSV-infected cells (29). Here we use a soluble version
of gE-gI and recombinant Fc molecules containing zero, one, or
two potential gE-gI-binding sites to further characterize the Fc
binding properties of gE-gI. The mutant Fc molecules were
made by altering six of the residues in the CH2-CH3 domain
interface of human Fc in either one or both of the Fc chains.
Four of the six residues that were mutated mediate specific, yet
diverse, interactions in the Fc binding interfaces for protein A,
protein G, rheumatoid factor, and FcRn (30–33), as well as
Fc-III, a high affinity Fc-binding peptide that was identified in
a phage display assay (52). In a sedimentation velocity centrif-
ugation assay, both wtFc and hdFc, which is a Fc molecule
containing one copy of the mutant subunit and one copy of the
wild-type subunit, bind gE-gI. gE-gI did not bind to nbFc,
which is a homodimeric Fc containing two copies of the mutant
subunit. These data confirm the importance of the CH2-CH3
domain interface of Fc in binding of gE-gI. Furthermore, they
imply that the gE-gI-binding site is contained, at least primar-
ily, within a single Fc subunit, unlike the mammalian FcR
receptors, which recognize a single binding site on Fc composed
FIG. 3. Analysis of the pH dependence of the gE-gI/Fc interac-
tion. KA1 (blue diamonds) and KA2 (pink circles) values were deter-
mined from kinetic analyses of surface plasmon resonance binding data
collected at pH values between 6.0 and 8.2. The best fit line for points
in the steepest portion of the pH-dependent affinity transition (pH 6.4,
6.6, 6.8, and 7.0) is shown for the intrinsic KA1 (corresponding to the
first gE-gI binding to Fc) and KA2 (corresponding to the second gE-gI
binding to Fc) values. The slopes for the lines are 2.1 and 2.2 for the first
and second binding sites, respectively.
TABLE I
Comparison of the kinetic constants and binding affinities of the gE-gIFc complex at different pH values
Intrinsic kinetic and binding constants were converted from apparent constants determined from global fitting of the biosensor kinetic data to
a bivalent ligand binding model as described under “Experimental Procedures.”
pH k1off k1on KD1 k2off k2on KD2
s1 M1 s1 nM s1 M1 s1 nM
8.2 5.0E04 2.1E03 240 3.6E04 5.3E02 676
8.0 5.1E04 2.1E03 246 3.6E04 5.4E02 669
7.8 5.1E04 2.0E03 261 3.7E04 5.1E02 732
7.6 5.6E04 2.0E03 283 4.2E04 5.3E02 796
7.4 6.3E04 1.8E03 343 4.8E04 5.2E02 928
7.2 7.9E04 1.7E03 474 6.2E04 4.9E02 1270
7.0 1.1E03 1.5E03 707 9.2E04 4.8E02 1910
6.8 1.7E03 1.4E03 1280 1.6E03 4.9E02 3330
6.6a 3.4E03 1.0E03 3300 4.9E03 4.8E02 10,200
6.4a 9.3E03 7.4E02 12600 1.9E01 4.6E03 41,200
6.2b 4.0E02 1.1E03 35700
6.0c
a Concentration of Fc was fixed during data analyses to improve the stability of the fits.
b Only one binding site was fit because fits allowing a second binding site were unstable.
c Kinetic constants could not be determined because the binding was too weak.
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of residues contributed by both Fc subunits (37).
To date all of the proteins whose contacts with Fc are medi-
ated through the CH2-CH3 domain interface can form 2:1 com-
plexes with Fc, with one molecule binding to each Fc subunit.
Our previous experiments using non-equilibrium and equilib-
rium gel filtration assays suggested that gE-gI forms 1:1 com-
plexes with IgG (28). Using three recombinant Fc molecules
(wtFc, hdFc, and nbFc) in a more sensitive assay involving
analytical ultracentrifugation, we show that gE-gI can form 2:1
complexes with wtFc and only 1:1 complexes with hdFc. The
data are also consistent with the formation of both 1:1 and 2:1
(gE-gIwtFc) complexes under non-saturating conditions of gE-
gI. Furthermore, surface plasmon resonance-based assays with
gE-gI and Fc support a bivalent ligand model with KD values of
343 and 928 nM for the first and second binding sites on wtFc,
respectively.
The finding that each chain of the Fc homodimer has a
binding site of similar affinity for the gE-gI heterodimer may
allow for antibody-mediated cross-linking of gE-gI proteins on
the surface of infected cells. Such cross-linking would involve
two gE-gI molecules bridged by IgG or, in the case of antibody
bipolar bridging, two gE-gI molecules bridged by IgG bound to
HSV antigens (e.g. gB or gD) via the antibody Fab arms. Anti-
body bipolar bridging between gE-gI and surface antigens in-
volving 1:1 gE-gIIgG complexes might still trigger the host
complement cascade through interactions of one of the CH2
domains of Fc with C1q. By contrast, in a 2:1 gE-gIIgG complex
in which each Fc chain interacts with a gE-gI molecule, the
binding of C1q is more likely to be sterically hindered, thus
preventing initiation of the complement cascade. Likewise, 2:1
gE-gIIgG complexes may be less accessible than 1:1 complexes
for interactions with host Fc receptors, such as FcRI, FcRII,
and FcRIII. Thus, formation of 2:1 complexes may enhance
the immune evasion effects that have been observed in the
presence of antibody bipolar bridging (19–22). The ability of
gE-gI to form either 1:1 or 2:1 complexes with IgG may be
related to the amount of gE-gI on the cell surface compared
with the amount of available IgG. The concentration of IgG in
the serum is 10-fold higher than the KD values for binding
gE-gI, thereby predicting that gE-gI would form primarily 1:1
complexes with free IgG. Anti-HSV IgG that is sequestered at
the cell surface through antigen recognition by the Fabs, how-
ever, would be present at a much lower concentration, allowing
for formation of 2:1 complexes with gE-gI. This potential dif-
ference in receptor:IgG stoichiometry provides a mechanism by
which an HSV-infected cell can distinguish between nonim-
mune IgG and anti-HSV IgG. The gE-gI cytoplasmic tails,
which contain potential signaling motifs including tyrosine-
based tetrapeptide motifs, dileucine motifs, and phosphoryla-
tion sites (7–13), are predicted to be arranged differently for 2:1
versus 1:1 complexes, resulting in a different set of downstream
effects. For example, in the case of 2:1, but not 1:1, complexes,
the cytoplasmic tails of cross-linked gE-gI molecules may be in
position to interact with each other or another protein.
Previous studies (28, 29) and the data reported here localize
the gE-gI-binding site to the CH2-CH3 domain interface of Fc, a
site that is recognized by a number of other Fc receptors in-
cluding FcRn, which binds to IgG with sharp pH dependence.
FcRn binds IgG in the acidic environment of intracellular ves-
icles or the lumen of the gut and releases it at the cell surface
(pH 7.4) (54–56). The sharp pH dependence of the rat FcRn/rat
Fc interaction has been attributed to three pairs of titrating
salt bridges in the binding interface, each involving an Fc
histidine and an acidic FcRn residue (Fc His-310/FcRn Glu-
117, Fc His-435/FcRn Glu-132, and Fc His-436/FcRn Asp-137)
(33, 45, 57–59). The Fc histidines are protonated under acidic
conditions, forming salt bridges with the negatively charged
residues on FcRn, which are disrupted upon deprotonation of
the histidines at neutral and basic pH, thereby leading to
dissociation of Fc from FcRn (33). His-435, which is involved in
the pH modulation of the rat FcRn-rat Fc complex, is conserved
in the human IgG subclasses hIgG1, hIgG2, and hIgG4, and is
also found in the common binding site at the CH2-CH3 domain
interface that has been described for many Fc-binding proteins
(33, 52). Although His-435 is an important contact residue for
Fc binding to protein A, protein G, and rheumatoid factor
(30–32), none of the interactions of these proteins with Fc are
sharply affected by changes of pH near neutral. Here we report
the unexpected result that the binding of Fc to the viral FcR
gE-gI is tightly pH-regulated, with the highest affinity at the
slightly basic pH of the extracellular milieu and undetectable
binding at the acidic pH of endosomes. At pH values between
7.4 and 8.2 the affinities of the two gE-gI-binding sites are
similar (KD1 	 240–340 nM and KD2 	 670–930 nM); however,
as the pH is decreased, the affinities become weaker until no
binding is detectable at pH 6.0 at concentrations up to 11 M.
An analysis of the pH-dependent affinity transition for the
gE-gI/Fc interaction suggests that two ionizable residues that
become protonated between pH 6.4 and 7.0 modulate this
sharply pH-dependent interaction. Because histidine residues
have a pKa near neutral pH, Fc His-435 could be involved in the
pH-dependent affinity transition. Although residues on gI must
affect Fc binding because gE-gI binds 100-fold more tightly to
Fc than gE alone, the finding that binding of isolated gE to Fc
is also pH-dependent suggests that at least some of the pH
dependence of the gE-gI interaction with Fc resides in gE
and/or Fc.
Mechanistic details for how a small change in pH modulates
the gE-gI/Fc interaction are unclear, but the present data allow
us to address some potential mechanisms. The possibility that
gE-gI itself dissociates at acidic pH as a result of a chemical
change at the interface of the gE-gI heterodimer is unlikely
because analytical ultracentrifugation results demonstrate
that the gE-gI heterodimer remains intact at acidic pH values
similar to intracellular endosomes. At pH 6, s* values of 3.45 S
for gE-gI and 2.6 S for gE were measured (data not shown).
These data are consistent with internalization experiments in
which the gE-gI complex was precipitated with an antibody to
either gE or gI (13). Another possible explanation for the pH
dependence of the gE-gI/Fc interaction is a change at the gE-
gI/Fc interface, either conformational or chemical, that dis-
rupts the interaction at acidic pH. Conformational changes in
Fc are unlikely since a comparison of the structures of Fc
molecules that have been solved at pH values between 4.1 and
8.0 revealed no significant differences (30–33, 37, 52, 60).
Thus, it is likely that the pH-dependent interaction between
gE-gI and Fc results either from chemical changes in Fc and/or
chemical or conformational changes in gE-gI. The small differ-
ence in the sedimentation coefficient of gE-gI at pH 7.8 versus
pH 6.0 (3.7 S at pH 7.8; 3.45 S at pH 6.0) suggests the possi-
bility of a pH-dependent conformational change in gE-gI. Fur-
ther structural, biophysical, and mutational analyses of gE-gI
and the gE-gI interaction with Fc will be required to elucidate
the mechanism by which gE-gI discriminates between Fc at
acidic and basic pH values.
The sharply pH-dependent affinity transition near neutral
pH of the gE-gI interaction with the Fc region of IgG is an
unusual feature of a protein/protein interaction, implying a
functional significance that could involve receptor-mediated
endocytosis. Receptor-mediated endocytosis is a process by
which receptors transport ligands (e.g. small molecules or pro-
teins) between the intracellular and extracellular environ-
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ments, often taking advantage of the differences in pH between
the cell surface and intracellular vesicles to regulate the proc-
ess (61). In addition to gE-gI/IgG, receptor-ligand pairs demon-
strating similarly strong pH-dependent interactions near neu-
tral pH include FcRn and IgG (tight binding at acidic but not
basic pH), apotransferrin and transferrin receptor (tight bind-
ing at acidic but not basic pH), and low density lipoprotein
(LDL) and its receptor (LDL receptor) (tight binding at basic
but not acidic pH). In each case, the pH-dependent receptor/
ligand interaction is critical for a function in intracellular traf-
ficking, such that the receptor-ligand complex either forms or
dissociates only at the slightly basic pH of the extracellular
milieu or inside acidic intracellular vesicles. For example, FcRn
and transferrin receptor only bind to their IgG or apotrans-
ferrin ligands in the acidic environment of endosomes and then
release their ligands upon exposure to the bloodstream (54–56,
62). Conversely, LDL binds its receptor at the cell surface and
then is released in acidic endosomes so that LDL receptor can
be recycled and LDL is targeted for degradation in lysosomes
(63). The gE-gI interaction with IgG shows the same trend in
pH-dependent binding as the interaction between LDL and
LDL receptor, suggesting a similar trafficking mechanism
whereby gE-gIIgG complexes are endocytosed from the cell
surface to enter acidic endosomes where IgG dissociates from
gE-gI and is then degraded in lysosomes.
In support of our proposal of receptor-mediated endocytosis
of IgG by gE-gI, several studies have investigated the endocy-
tosis of gE, gI, and gE-gI. Experiments using transfected and/or
infected cells demonstrated that the gE proteins of HSV, PRV,
and VZV and the gI proteins of VZV and PRV undergo endo-
cytosis (7–10, 12, 13, 64–66). Furthermore, the colocalization
of VZV gE with transferrin receptor during endocytosis and
recycling in transfected cells suggests that gE travels from the
plasma membrane to the early endosomes and then is recycled
back to the cell surface (9). When both VZV gE and gI are
expressed in HeLa cells, gE and gI colocalize during endocyto-
sis and recycling with evidence from quantitative internaliza-
tion assays suggesting that gE and gI are internalized as a
complex (13). Additional experiments support the suggestion
that gE and/or gE-gI heterodimers function in receptor-medi-
ated endocytosis of IgG followed by its degradation. VZV gE-
expressing HeLa cells bind IgG Fc at the cell surface, which
becomes undetectable both inside and outside the cells upon
incubation at 37 °C, consistent with intracellular degradation
(9). Although internalization of gE or the gE-gI complex has not
been shown to be dependent on antibody binding via Fc with or
without antibody bipolar bridging, it is possible that antibody
binding affects the endocytosis of these molecules by increasing
the efficiency or kinetics of internalization, for example.
There are several possibilities for how gE-gI-mediated endo-
cytosis of anti-HSV antibodies could facilitate immune evasion
by HSV. Binding of an anti-HSV antibody via its Fab arms to
an HSV antigen and via its Fc domain to gE-gI might induce
internalization of the entire gE-gIIgGantigen complex,
thereby removing HSV antigens from the cell surface and thus
reducingantibody-mediatedimmuneresponsessuchasantibody-
dependent cell-mediated cytotoxicity or antibody-dependent
complement-mediated lysis. In PRV-infected monocytes, incu-
bation with anti-PRV antibodies resulted in the aggregation
and internalization of many cell surface proteins and in the
inhibition of antibody-dependent complement-mediated lysis,
which was dependent on IgG binding by PRV gE-gI (67, 68).
The finding that HSV-1 gE-gI binding of IgG is pH-dependent
strongly suggests another hypothesis for how endocytosis of
gE-gI-antibody complexes hinders the host immune response,
namely that IgG molecules and IgG-antigen complexes brought
into acidic compartments by gE-gI are targeted for degradation
in lysosomes after low pH-induced dissociation from gE-gI,
thereby reducing the ability of the host to mount antibody-de-
pendent immune responses and to make immune responses to
viral antigens.
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